334 related articles for article (PubMed ID: 24174972)
41. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
Lim WH; Russ GR; Coates PT
Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
[TBL] [Abstract][Full Text] [Related]
42. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients.
Boyle GJ; Michaels MG; Webber SA; Knisely AS; Kurland G; Cipriani LA; Griffith BP; Fricker FJ
J Pediatr; 1997 Aug; 131(2):309-13. PubMed ID: 9290623
[TBL] [Abstract][Full Text] [Related]
43. Posttransplant lymphoproliferative disease following liver transplantation.
Kamdar KY; Rooney CM; Heslop HE
Curr Opin Organ Transplant; 2011 Jun; 16(3):274-80. PubMed ID: 21467936
[TBL] [Abstract][Full Text] [Related]
44. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically.
Pitman SD; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Berdeja JG; Weiss LM; Wang J
Am J Surg Pathol; 2006 Apr; 30(4):470-6. PubMed ID: 16625093
[TBL] [Abstract][Full Text] [Related]
45. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
46. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
Wistinghausen B; Gross TG; Bollard C
Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715
[TBL] [Abstract][Full Text] [Related]
47. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
48. Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
Bosse RC; Franke AJ; Paul Skelton W; Woody LE; Bishnoi R; Wang Y; Bhaduri-McIntosh S; Rajderkar D; Shih R; Dang NH; Slayton WB
Pediatr Transplant; 2020 Aug; 24(5):e13747. PubMed ID: 32497335
[TBL] [Abstract][Full Text] [Related]
49. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
[TBL] [Abstract][Full Text] [Related]
50. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
[TBL] [Abstract][Full Text] [Related]
51. Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.
Major A; Kamdar M
Curr Treat Options Oncol; 2018 May; 19(7):33. PubMed ID: 29797086
[TBL] [Abstract][Full Text] [Related]
52. Management of post-transplant lymphoproliferative disorders.
Llaurador G; McLaughlin L; Wistinghausen B
Curr Opin Pediatr; 2017 Feb; 29(1):34-40. PubMed ID: 27906865
[TBL] [Abstract][Full Text] [Related]
53. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
54. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.
Limaye AP; Huang ML; Atienza EE; Ferrenberg JM; Corey L
J Clin Microbiol; 1999 Apr; 37(4):1113-6. PubMed ID: 10074534
[TBL] [Abstract][Full Text] [Related]
55. Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: A multicentre international experience.
Guerra-García P; Bomken S; Ling R; Lazareva A; Gupte G; Amrolia P; Andrés M; Diez-Sebastián J; Taj MM
Pediatr Blood Cancer; 2024 Aug; 71(8):e31053. PubMed ID: 38757407
[TBL] [Abstract][Full Text] [Related]
56. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for adenotonsillar hypertrophy in children following solid organ transplantation.
Shapiro NL; Strocker AM; Bhattacharyya N
Int J Pediatr Otorhinolaryngol; 2003 Feb; 67(2):151-5. PubMed ID: 12623151
[TBL] [Abstract][Full Text] [Related]
58. Post-transplant lymphoproliferative disorder after solid-organ transplant in children.
Absalon MJ; Khoury RA; Phillips CL
Semin Pediatr Surg; 2017 Aug; 26(4):257-266. PubMed ID: 28964482
[TBL] [Abstract][Full Text] [Related]
59. Management of post-transplant lymphoproliferative disorders.
DeStefano CB; Desai SH; Shenoy AG; Catlett JP
Br J Haematol; 2018 Aug; 182(3):330-343. PubMed ID: 29741774
[TBL] [Abstract][Full Text] [Related]
60. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.
Preiksaitis JK; Keay S
Clin Infect Dis; 2001 Jul; 33 Suppl 1():S38-46. PubMed ID: 11389521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
